Advertisement
Screener

ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) Overview

ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) Overview

  • 1 Apr 2026: Period ending 30 Jun 2026; Estimate (m); Actual -0.25; Beat / miss (m).
  • 1 Jan 2026: Period ending 31 Mar 2026; Estimate (m); Actual -0.13; Beat / miss (m).
  • 1 Jul 2025: Period ending 30 Sept 2025; Estimate (m); Actual 0.06; Beat / miss (m).
  • 1 Apr 2025: Period ending 30 Jun 2025; Estimate (m); Actual -0.17; Beat / miss (m).

Stock Price Chart

View more →

Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close

$11.79$14.31$17.37$21.08$25.58$31.052025-11-062026-11-06$2.22$3.93$6.94$12.27$21.69$38.322021-11-082026-11-06$2.22$4.45$8.89$17.78$35.56$71.132019-06-272026-11-06$2.22$4.45$8.89$17.78$35.56$71.132019-06-272026-11-06$2.22$4.45$8.89$17.78$35.56$71.132019-06-272026-11-06

Logarithmic scale. Both lines share the same starting value for the selected range.

Last close
$27.97
Previous close
$28.77
Change
-$0.80
Change (%)
-2.78%
Close date
2026-11-06
Previous close date
2026-09-29
Open
(m)
Day high
(m)
Day low
(m)
Last session volume
(m)
Last session value
(m)
Currency
USD
Price basis
split-adjusted
Volume basis
(m)

Performance

View more →

Cumulative total returns · 2026-09-29

YTD

ADPT
+77.16%
S&P 500
(m)

1 year

ADPT
+113.74%
S&P 500
(m)

3 years

ADPT
+427.89%
S&P 500
(m)

5 years

ADPT
-11.37%
S&P 500
(m)

Earnings trends

View more →

Earnings per share

USD / share · As filed

30 Jun 2026 ○ Estimate (m) ● Actual -0.25

-0.33-0.19-0.040.100.2431 Mar 2025: estimate (m); actual -0.2031 Mar 2025(m)30 Jun 2025: estimate (m); actual -0.1730 Jun 2025(m)30 Sept 2025: estimate (m); actual 0.0630 Sept 2025(m)31 Mar 2026: estimate (m); actual -0.1331 Mar 2026(m)30 Jun 2026: estimate (m); actual -0.2530 Jun 2026(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Apr 202630 Jun 2026(m)-0.25(m)(m)
1 Jan 202631 Mar 2026(m)-0.13(m)(m)
1 Jul 202530 Sept 2025(m)0.06(m)(m)
1 Apr 202530 Jun 2025(m)-0.17(m)(m)
1 Jan 202531 Mar 2025(m)-0.20(m)(m)

31 Dec 2025 ○ Estimate (m) ● Actual -0.39

-1.64-1.28-0.93-0.57-0.2131 Dec 2021: estimate (m); actual -1.4831 Dec 2021(m)31 Dec 2022: estimate (m); actual -1.4031 Dec 2022(m)31 Dec 2023: estimate (m); actual -1.5631 Dec 2023(m)31 Dec 2024: estimate (m); actual -1.0831 Dec 2024(m)31 Dec 2025: estimate (m); actual -0.3931 Dec 2025(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Jan 202531 Dec 2025(m)-0.39(m)(m)
1 Jan 202431 Dec 2024(m)-1.08(m)(m)
1 Jan 202331 Dec 2023(m)-1.56(m)(m)
1 Jan 202231 Dec 2022(m)-1.40(m)(m)
1 Jan 202131 Dec 2021(m)-1.48(m)(m)

Revenue vs. Earnings

USD

30 Jun 2026 ■ Revenue 71.55M ■ Earnings -39.79M — Profit margin -55.61%

-55.84M-56.6%-0.55M-34.0%54.74M-11.4%110.02M11.2%30 Sept 2025: revenue 93.97M; earnings 9.55M; profit margin 10.16%30 Sept 202531 Dec 2025: revenue 71.68M*; earnings -13.58M*; profit margin -18.94%*; Revenue: Annual amount − nine-month amount; Earnings: Annual amount − nine-month amount; period 2025-10-01 to 2025-12-31; USD.31 Dec 202531 Mar 2026: revenue 70.87M; earnings -20.03M; profit margin -28.27%31 Mar 202630 Jun 2026: revenue 71.55M; earnings -39.79M; profit margin -55.61%30 Jun 2026

31 Dec 2025 ■ Revenue 276.98M ■ Earnings -59.50M — Profit margin -21.48%

-285.52M-133.3%-77.93M-95.7%129.66M-58.1%337.24M-20.5%31 Dec 2022: revenue 185.31M; earnings -200.19M; profit margin -108.03%31 Dec 202231 Dec 2023: revenue 170.28M; earnings -225.25M; profit margin -132.29%31 Dec 202331 Dec 2024: revenue 178.96M; earnings -159.49M; profit margin -89.12%31 Dec 202431 Dec 2025: revenue 276.98M; earnings -59.50M; profit margin -21.48%31 Dec 2025

Analyst insights

View more →
RatingsBuyHoldSellOther ratingsLast CloseAverage TargetUpsideHigh TargetLow Target
(m)(m)(m)(m)(m)$27.97(m)(m)(m)(m)
Past 12 Months12 Month ForecastLast Close$27.97High(m)Average(m)Low(m)2025-11-062026-11-06

Recent news

View more →

(m)

YouTube videos mentioning ADPT

View more →

(m)

Statistics

View more →

Retained observations as of 2026-11-11; financial period ending 30 Jun 2026.

Forward P/E
(m)
PEG ratio · 5-year expected
(m)
Shares held by insiders
(m)
Insider transactions · change (%)
(m)
Shares held by institutions
(m)
Institutional transactions · change (%)
(m)
Diluted EPS · 12 month
(m)
EPS estimate · next quarter
(m)
EPS estimate · next year
(m)
EPS growth · current annual estimate
(m)
EPS growth · next annual estimate
(m)
EPS growth · next 5 years expected
(m)
EPS growth · past 3 years annualized
(m)
EPS growth · past 5 years annualized
(m)
EPS change · 12 months vs prior year
(m)
EPS change · latest quarter vs previous quarter
(m)
Latest earnings report date
(m)
EPS surprise · latest reported quarter
(m)
Net income · 12 month
$-63.85M
Profit margin
-20.73%
Return on assets · 12 month
-11.23%
Index membership
(m)
Employees
624.00
IPO date
(m)
Options available
(m)
Shortable
(m)
Analyst recommendation
(m)
Analyst target price
(m)
Price volatility · week
(m)
Price volatility · month
(m)
Average true range · 14 sessions
(m)
Relative strength index · 14 sessions
(m)
Relative volume
(m)
Average daily volume
2.29M
Latest session volume
(m)
Last session value
(m)
30 days ago session value
(m)
1 year ago session value
(m)
Number of trades
(m)
Total return · week
2.53%*
Total return · month
14.21%*
Total return · quarter
34.44%*
Total return · half year
131.83%*
Total return · year to date
77.16%*
Total return · 1 year
113.74%*
Total return · 3 years
427.89%*
Total return · 5 years
-11.37%*
Market cap
(m)
Book value per share · latest quarter
(m)
Price / cash · latest quarter
(m)
Enterprise value
(m)
Enterprise value / revenue
(m)
Enterprise value / EBITDA
(m)
Dividend · 12 months per share
(m)
Dividend ex-date
(m)
Next dividend ex-date
(m)
Next dividend amount per share
(m)
Dividend growth · 3 years annualized
(m)
Dividend growth · 5 years annualized
(m)
Revenue · 12 month
$308.08M
Revenue growth · past 3 years annualized
(m)
Revenue growth · past 5 years annualized
(m)
Revenue change · 12 months vs prior year
(m)
Revenue change · latest quarter vs previous quarter
(m)
Revenue surprise · latest reported quarter
(m)
Levered free cash flow · 12 month
(m)
Debt / equity · latest quarter
(m)
Long-term debt / equity · latest quarter
0.00%*
Return on equity · 12 month
(m)
Return on invested capital · 12 months
(m)
Previous close
(m)
Latest closing price
(m)
Latest session change (%)
(m)
52-week high
(m)
52-week low
(m)
Price vs 20-session moving average
(m)
Price vs 50-session moving average
(m)
Price vs 200-session moving average
(m)
Float shares
(m)
Short float (%)
(m)
Short ratio (days to cover)
(m)
Short interest (shares)
(m)

Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.

Holders breakdown

View more →
BreakdownOwnership
(m)Shares held by all insiders
(m)Shares held by institutions
(m)Float held by institutions
(m)Institutions holding shares

Other holders

(m)

View more →

Insider holders

(m)

View more →

Top institutional holders

(m)

View more →

Top mutual fund holders

(m)

View more →

ADAPTIVE BIOTECHNOLOGIES CORPORATION Overview

View more →

(m)

(m)

SEC CIK
1478320
Industry (SIC)
2836 Biological Products, (No Diagnostic Substances)
Country of operation
United States
Business address
1165 EASTLAKE AVE E, SEATTLE, Washington, 98109, United States
Fiscal year end
1231
Phone
206-659-0067

Similar stocks

Stock NameCountryMarket CapPE Ratio
IOVANCE BIOTHERAPEUTICS, INC. (IOVA)United States$4.897B-6.51
CRISPR Therapeutics AG (CRSP)$5.390B-11.68
Relay Therapeutics, Inc. (RLAY)United States$3.884B-14.30
Scholar Rock Holding Corp (SRRK)United States$5.920B-16.37
CG Oncology, Inc. (CGON)United States$6.095B-27.95
Tarsus Pharmaceuticals, Inc. (TARS)United States$3.329B-58.60
Denali Therapeutics Inc. (DNLI)United States$3.274B-8.04
Beam Therapeutics Inc. (BEAM)United States$2.549B-41.51
Immunovant, Inc. (IMVT)United States$7.028B-14.78
Greenland Mines Ltd (GRML)United States$2.362B